- JP-listed companies
- Balance sheet
(130A) Balance sheet
Market cap
¥3.1B
P/E ratio
-5.4x
Veritas In Silico develops small-molecule drugs targeting messenger RNA using its ibVIS platform, partnering with major pharmaceutical companies like Takeda and Shionogi.
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Cash and cash equivalents | - | 1,689 | 1,484 | 1,549 | 2,173 | 1,825 |
| Total current assets | - | 1,729 | 1,547 | 1,629 | 2,232 | 1,865 |
| Property, plant and equipment, net | - | 20 | 48 | 24 | 14 | - |
| Total non-current assets | - | 26 | 51 | 26 | 17 | 20 |
| Total assets | - | 1,755 | 1,599 | 1,656 | 2,249 | 1,885 |
| Total current liabilities | - | 71 | 56 | 80 | 39 | 101 |
| Total liabilities | - | 71 | 56 | 80 | 39 | 101 |
| Retained earnings | - | -530 | -141 | 33 | -203 | -629 |
| Stockholders' equity | 516 | 1,684 | 1,543 | 1,576 | 2,210 | 1,784 |